Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.94Last Year’s EPS
-0.52Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: -5.62%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant revenue growth, profitability, and progress in clinical trials. Despite a slight decline in the rare franchise and anticipated decrease in gross margins, the strong performance and guidance in key areas like the TTR franchise and R&D pipeline suggest a positive outlook.Company Guidance
During the call, Alnylam Pharmaceuticals provided guidance for 2025, projecting combined net product revenues of $2.05 billion to $2.25 billion, representing a 31% growth compared to 2024. The TTR franchise, including the anticipated approval and launch of AMVUTTRA for ATTR cardiomyopathy, is expected to drive growth, with projected sales between $1.6 billion and $1.725 billion, marking a 36% increase from 2024. The Rare franchise is projected to generate $450 million to $525 million, reflecting a 15% growth. Collaboration and royalty revenue is expected to be between $650 million and $750 million, with a significant portion driven by a $300 million milestone payment from Roche. Alnylam also aims to deliver non-GAAP operating income profitability in 2025, with combined non-GAAP R&D and SG&A expenses projected to grow 17% at the midpoint of their guidance range.Strong Revenue Growth
Alnylam achieved combined net product revenues of over $1.6 billion, marking a 33% growth compared to 2023 and reaching the upper end of their revised guidance range.
Record Non-GAAP Operating Income
The company delivered $95 million in non-GAAP operating income, a significant milestone indicating profitability for the full year.
Positive Phase 3 Study Results
HELIOS-B Phase 3 study results for vutrisiran in ATTR cardiomyopathy were highly positive, leading to submissions of global regulatory filings.
TTR Franchise Growth
The TTR franchise achieved $343 million in global net product revenues in Q4, representing a 35% increase compared to Q4 2023.
R&D Pipeline Expansion
Alnylam advanced its robust pipeline, including the initiation of four new Phase 1 programs and progress in multiple clinical areas.
---
ALNY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ALNY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $265.96 | $264.89 | -0.40% |
| Oct 31, 2024 | $281.49 | $266.59 | -5.29% |
| Aug 01, 2024 | $237.46 | $268.61 | +13.12% |
| May 02, 2024 | $149.96 | $150.31 | +0.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Alnylam Pharmaceuticals (ALNY) report earnings?
Alnylam Pharmaceuticals (ALNY) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Alnylam Pharmaceuticals (ALNY) earnings time?
Alnylam Pharmaceuticals (ALNY) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALNY EPS forecast?
ALNY EPS forecast for the fiscal quarter 2025 (Q1) is -0.94.
---